Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 1;18(2):156-164.
doi: 10.18502/ijhoscr.v18i2.15371.

Potential Diagnostic Value of Abnormal Pyroptosis Genes Expression in Myelodysplastic Syndromes (MDS): A Primary Observational Cohort Study

Affiliations

Potential Diagnostic Value of Abnormal Pyroptosis Genes Expression in Myelodysplastic Syndromes (MDS): A Primary Observational Cohort Study

Mohammad Soltani et al. Int J Hematol Oncol Stem Cell Res. .

Abstract

Background: Myelodysplastic syndromes (MDS) are determined by ineffective hematopoiesis and bone marrow cytological dysplasia with somatic gene mutations and chromosomal abnormalities. Accumulating evidence has revealed the pivotal role of NLRP3 inflammasome activation and pyroptotic cell death in the pathogenesis of MDS. Although MDS can be diagnosed with a variety of morphologic and cytogenetic tests, most of these tests have limitations or problems in practice. Materials and Methods: In the present study, we evaluated the expression of genes that form the inflammasome (NLRP3, ASC, and CASP1) in bone marrow specimens of MDS patients and compared the results with those of other leukemias to evaluate their diagnostic value for MDS. Primary samples of this observational cohort study were collected from aspiration samples of patients with myelodysplastic syndromes (27 cases) and patients with non-myelodysplastic syndrome hematological cancers (45 cases). After RNA extraction and c.DNA synthesis, candidate transcripts and housekeeping transcripts were measured by real-time PCR method (SYBER Green assay). Using Kruskal-Wallis the relative gene expressions were compared and differences with p value less than 0.05 were considered as significant. Discrimination capability, cut-off, and area under curve (AUC) of all markers were analyzed with recessive operation curve (ROC) analysis. Results: We found that Caspase-1 and ASC genes expressed at more levels in MDS specimens compared to non-MDS hematological malignancies. A relative average expression of 10.22 with a p-value of 0.001 and 1.86 with p=0.019 was detected for Caspase-1 and ASC, respectively. ROC curve analysis shows an AUC of 0.739 with p=0.0001 for Caspase-1 and an AUC of 0.665 with p=0.0139 for ASC to MDS discrimination. Conclusion: Our results show that Caspase-1 and ASC gene expression levels can be used as potential biomarkers for MDS diagnosis. Prospective studies with large sample numbers are suggested.

Keywords: ASC; Casapase1; Inflammasome; Myelodysplastic Syndromes; NLRP3; Pyroptosis.

PubMed Disclaimer

Conflict of interest statement

The authors do not have any conflicts of interest.

Figures

Figure 1
Figure 1
The relative expression of genes related to pyroptosis cell death (ASC, NLRP3, and CASP1) in patients with MDS compared to the control group. The gene expression level of NLRP3 (A), ASC (B) and CASP1 (C) in the bone marrow (BM) aspiration samples of 27 MDS patients (N = 27) and the control group (N = 45) including 11 patients with acute lymphocytic leukemia (ALL), 14 patients with acute myeloid leukemia (AML), 7 patients with chronic lymphocytic leukemia (CLL), 5 patients with chronic myeloid leukemia (CML), 6 patients with multiple myeloma (MM), and 2 patients with hairy cell leukemia (HCL). Asterisks represent for statistical significance (* means p<0.05 and ** means p<0.001).
Figure 2
Figure 2
ROC curves of sample sets analyzed for relative expression levels of ASC (A) and CASP1 (B). Area under curve, cut-off value, sensitivity and specificity for all studied genes are shown.

Similar articles

Cited by

  • Immune-dysregulation harnessing in myeloid neoplasms.
    Sharifi MJ, Xu L, Nasiri N, Ashja-Arvan M, Soleimanzadeh H, Ganjalikhani-Hakemi M. Sharifi MJ, et al. Cancer Med. 2024 Sep;13(17):e70152. doi: 10.1002/cam4.70152. Cancer Med. 2024. PMID: 39254117 Free PMC article. Review.

References

    1. Tanaka TN, Bejar R. MDS overlap disorders and diagnostic boundaries. Blood. 2019;133(10):1086–95. - PubMed
    1. Bejar R. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing? Curr Hematol Malig Rep. 2015;10(3):282–91. - PMC - PubMed
    1. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23(11):2183–6. - PubMed
    1. Font P, Loscertales J, Benavente C, et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol. 2013;92(1):19–24. - PubMed
    1. Mufti GJ, McLornan DP, van de Loosdrecht AA, et al. Diagnostic algorithm for lower-risk myelodysplastic syndromes. Leukemia. 2018;32(8):1679–96. - PubMed

LinkOut - more resources